Market Place
Sourcing Support
All News #Library
Biotech
Atossa Therapeutics Reports Q4 & FY 2025 Results and Update
25 Mar 2026 //
PR NEWSWIRE
Atossa Highlights 2025 Wins, Outlines 2026 Outlook
11 Feb 2026 //
PR NEWSWIRE
FDA Clears Atossa (Z)-Endoxifen IND for Metastatic Breast Cancer
06 Jan 2026 //
PR NEWSWIRE
Atossa Pharma Receives 2025 Clinical Trials Arena Award
17 Dec 2025 //
PR NEWSWIRE BIO
Atossa Therapeutics Secures U.S. Patent for Oral (Z)-Endoxifen
09 Dec 2025 //
PR NEWSWIRE
Atossa Accelerates (Z)-Endoxifen for Breast Cancer
04 Dec 2025 //
PR NEWSWIRE
Insilico Medicine & Atossa Therapeutics Publish AI Study
02 Dec 2025 //
PR NEWSWIRE
Atossa Therapeutics Showcases RECAST™ DCIS Trial Progress
21 Oct 2025 //
PR NEWSWIRE
Atossa Boosts Z-Endoxifen Global Patent Strategy With Israeli
13 Oct 2025 //
PR NEWSWIRE
Atossa Pharma Appoints Janet R. Rea As Senior Vice President
01 Oct 2025 //
PR NEWSWIRE
Atossa Speeds Up Low-Dose (Z)-Endoxifen Breast Cancer Strategy
08 Sep 2025 //
PR NEWSWIRE
Atossa Picks PSI for Pivotal (Z)-Endoxifen Breast Cancer Study
20 Aug 2025 //
PR NEWSWIRE
Atossa Reports I-SPY 2 Results On Low-Dose Z-Endoxifen
14 May 2025 //
PR NEWSWIRE
Nona Bio, Atossa Partner for Advance Breast Cancer Therapies
10 Apr 2025 //
PR NEWSWIRE
Atossa & Quantum Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen
21 Mar 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.